Mitochondrial Nephropathy With m. 5538G>A Mutation Within the tRNA ‐Trp Region Assessed by Mitochondrial Function Analysis: A Case Report
Nephrology · 2025
DOI: 10.1111/nep.70153 ↗Kurz gefasst
Fallbericht in der Zeitschrift Nephrology, 2025. Verfasst von Mari Ikeda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Kameda Medical Center, Chiba, Japan. Hauptthemen laut MEDLINE: Mutation, Mitochondria, Mitochondrial Diseases, Glomerulosclerosis, Focal Segmental. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Mitochondrial nephropathy (MIT‐N) presents with urinary protein in more than 90% of cases and reduced kidney function in approximately 70%. Coenzyme Q10 is effective only in a subset of patients. Herein, we report the first case of MIT‐N treated with imeglimin, a drug known to improve mitochondrial function. A 25‐year‐old man had been diagnosed with minor glomerular abnormality at age 15. As his urinary protein increased (urine protein creatinine ratio 2.2 g/gCre) and decreased kidney function (serum creatinine 1.24 mg/dL), a kidney biopsy was performed. Light microscopy revealed focal segmental glomerulosclerosis, and electron microscopy demonstrated numerous abnormal mitochondria in podocytes. Serum and cerebrospinal fluid lactate levels were 27.8 and 35.5 mg/dL, respectively, raising suspicion of mitochondrial disease. Genetic analysis confirmed the m.5538G>A mutation in the tRNA‐Trp region in the blood, urine and skin fibroblasts. Additionally, the enzymatic activity of mitochondrial respiratory chain complex (C) I–IV in dermal fibroblasts showed reduced activity of CIII and CIV. The patient was treated with olmesartan, dapagliflozin and imeglimin for chronic kidney disease with persistent urinary protein levels and new‐onset diabetes, respectively. Approximately 1 year after starting treatment with imeglimin, the rate of kidney function decline accelerated, although proteinuria decreased. While it is difficult to attribute a renoprotective effect solely to imeglimin, further studies are needed to verify its long‐term efficacy in MIT‐N.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Kameda Medical Center, Chiba, Japan.
- Department of Nephrology, National Hospital Organization Chiba-Higashi National Hospital, Chiba, Japan.
- Department of Nephrology, Yokohama Rosai Hospital, Kanagawa, Japan.
- Department of Mental Retardation and Birth Defect Research, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan.
- Diagnostics and Therapeutic of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- Center for Medical Genetics, Department of Metabolism, Chiba Children's Hospital, Chiba, Japan.
ORCID-Profile: Yasushi Okazaki, Kei Murayama
Zitieren
APA
Ikeda, M., Imasawa, T., Akanuma, T., Goto, Y. I., Okazaki, Y., Murayama, K., Ohara, M., & Suzuki, T. (2025). Mitochondrial Nephropathy With m. 5538G>A Mutation Within the tRNA ‐Trp Region Assessed by Mitochondrial Function Analysis: A Case Report. Nephrology. https://doi.org/10.1111/nep.70153
Vancouver
Ikeda M, Imasawa T, Akanuma T, Goto YI, Okazaki Y, Murayama K, et al. Mitochondrial Nephropathy With m. 5538G>A Mutation Within the tRNA ‐Trp Region Assessed by Mitochondrial Function Analysis: A Case Report. Nephrology. 2025. doi:10.1111/nep.70153
BibTeX
@article{Ikeda2025,
author = {Ikeda, Mari and Imasawa, Toshiyuki and Akanuma, Takafumi and Goto, Yu-Ichi and Okazaki, Yasushi and Murayama, Kei and Ohara, Mamiko and Suzuki, Tomo},
title = {Mitochondrial Nephropathy With m. 5538G>A Mutation Within the tRNA ‐Trp Region Assessed by Mitochondrial Function Analysis: A Case Report},
journal = {Nephrology},
year = {2025},
doi = {10.1111/nep.70153}
}
EUVIMED